Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

BACKGROUND: Immune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune responses and increase the effectiveness of immunotherapy. However, the effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Jinyu, Peng, Jin, Feng, Jie, Maurer, Jochen, Li, Xiao, Li, Yan, Yao, Shu, Chu, Ran, Pan, Xiyu, Li, Junting, Zhang, Ting, Liu, Lu, Zhang, Qing, Yuan, Zeng, Bu, Hualei, Song, Kun, Kong, Beihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499579/
https://www.ncbi.nlm.nih.gov/pubmed/34620163
http://dx.doi.org/10.1186/s12967-021-03073-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499579/
https://www.ncbi.nlm.nih.gov/pubmed/34620163
http://dx.doi.org/10.1186/s12967-021-03073-0

Ejemplares similares